0001661181-21-000062.txt : 20210720 0001661181-21-000062.hdr.sgml : 20210720 20210720204500 ACCESSION NUMBER: 0001661181-21-000062 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210716 FILED AS OF DATE: 20210720 DATE AS OF CHANGE: 20210720 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gillheeney Gary S. CENTRAL INDEX KEY: 0001757373 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37906 FILM NUMBER: 211102435 MAIL ADDRESS: STREET 1: C/O ORGANOGENESIS INC. STREET 2: 85 DAN ROAD CITY: CANTON STATE: MA ZIP: 02021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Organogenesis Holdings Inc. CENTRAL INDEX KEY: 0001661181 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 85 DAN ROAD CITY: CANTON STATE: MA ZIP: 02021 BUSINESS PHONE: 781-575-0775 MAIL ADDRESS: STREET 1: 85 DAN ROAD CITY: CANTON STATE: MA ZIP: 02021 FORMER COMPANY: FORMER CONFORMED NAME: Avista Healthcare Public Acquisition Corp. DATE OF NAME CHANGE: 20151215 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2021-07-16 0001661181 Organogenesis Holdings Inc. ORGO 0001757373 Gillheeney Gary S. C/O ORGANOGENESIS HOLDINGS INC. 85 DAN ROAD CANTON MA 02021 1 1 0 0 President and CEO Class A Common Stock 2021-07-16 4 M 0 24313 0.99 A 156230 D Class A Common Stock 2021-07-16 4 M 0 115450 4.04 A 271680 D Class A Common Stock 2021-07-16 4 S 0 110329 14.58 D 161351 D Class A Common Stock 2021-07-16 4 S 0 29434 15.33 D 131917 D Class A Common Stock 2021-07-19 4 M 0 160237 0.99 A 292154 D Class A Common Stock 2021-07-19 4 S 0 160237 14.02 D 131917 D Stock Option (Right to Buy) 0.99 2021-07-16 4 M 0 24313 0.0 D 2023-07-25 Class A Common Stock 24313 680097 D Stock Option (Right to Buy) 4.04 2021-07-16 4 M 0 115450 0 D 2030-04-22 Class A Common Stock 115450 465392 D Stock Option (Right to Buy) 0.99 2021-07-19 4 M 0 160237 0.0 D 2023-07-25 Class A Common Stock 160237 519860 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2021. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.27 to $14.99, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.85, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.61 to $14.38, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. 100% of the shares subject to the option are fully vested and exercisable. The option became and continues to become exercisable in equal annual installments over four years beginning April 1, 2020. /s/ Stacie S. Aarestad, Attorney-in-Fact 2021-07-20